License: Creative Commons Attribution 4.0 PDF - Published Version (730kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-527643
- DOI to cite this document:
- 10.5283/epub.52764
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with adverse outcomes that have barely improved over the last decade. About half of all patients present with metastasis at the time of diagnosis, and the 5-year overall survival rate across all stages is only 6%. Innovative in vivo research models are necessary to combat this cancer and to discover novel treatment strategies. ...
Owner only: item control page